News

Mallinckrodt buys immunotherapy group Therakos for $1.33bn


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Mallinckrodt buys immunotherapy group Therakos for $1.33bn

 

Date: 11/08/2015


UK speciality pharma Mallinkcrodt is delving deeper into the hospital market through a $1.33 billion agreement to snap up US immunotherapy group Therakos.

The deal gives Mallinckrodt access to Therkos’ key cell therapy platform approved for the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma (CTCL) in patients who have not responded to other forms of treatment.

For more click here

Source: PharmaTimes

© Catalyst Innovation Portal 2019